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The anticoagulant effect of heparin is dependent on thelevel of antithrombin III (AT III). Argatroban (Novastan;Mitsubishi Tokyo Chemical Corporation, Tokyo, Japan)is a unique synthetic direct thrombin inhibitor developed
in Japan.1 Argatroban requires no AT III to exert its antithrombin
effect.2,3 We used this drug as an anticoagulant during cardiopul-
monary bypass (CPB) in a patient with AT III deficiency. 
Clinical Summary 
A 44-year-old man was transferred to our hospital with shock and
multiorgan failure on December 31, 1999. Laboratory studies of
his blood revealed severe liver dysfunction probably due to fulmi-
nant hepatitis. Echocardiography revealed severe aortic regurgita-
tion and vegetations on the aortic valve, and infective endocarditis
was diagnosed. Continuous hemodialysis and filtration for renal
failure were performed for 12 days and plasma exchange for
hepatic failure was performed twice. Gradually, his general condi-
tion improved. Aortic valve replacement was scheduled for March
21, 2000. A preoperative echocardiogram showed that the left ven-
tricular diameter was 67.0 mm during diastole and 43.3 mm dur-
ing systole, and the left ventricular ejection fraction was 63.6%
with severe aortic regurgitation. Liver dysfunction including coag-
ulopathy (prothrombin activity 67.4%, activated partial thrombo-
plastin activity <20.0%) and AT III deficiency (46.4%) persisited.
Heparinization with AT III substitution therapy was discussed.
However, if this therapy was used for anticoagulation during CPB,
we believed that AT III and coagulant factors would be consumed
and pathologic thrombosis or bleeding tendency would occur.4
After obtaining informed consent, we decided to use argatroban as
an anticoagulant during CPB. 
The extracorporeal circuit consisted of a roller pump, a silicone
membrane artificial lung (HPO-20RHF-C; Senko Ika, Tokyo,
Japan), and a hard reservoir. These components were connected
with a heparin-coated polyethylene tube. No argatroban was added
to the pump prime. A bolus injection of argatroban, 0.1 mg/kg, fol-
lowed by a continuous infusion at 5 to 10 µg · kg–1 · min–1, was
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used. After the bolus injection, CPB with mild hypothermia was
started. A conventional aortic valve replacement was performed
with a stented porcine valve. The CPB and aortic crossclamp times
were 167 and 114 minutes, respectively. During CPB, the dose of
argatroban was adjusted to maintain the activated clotting time
(ACT; Hemochron, International Technidyne Corporation [ITC],
Kent, United Kingdom) between 300 and 400 seconds (Figure 1).
Argatroban was stopped at the termination of CPB. Hypoxia and
pathologic thrombosis did not occur during CPB. However, after
CPB, a small thrombus in the reservoir was recognized. The ACT
1 hour after CPB was 278 seconds. Only 2 units of packed red
blood cells were transfused. Postoperative bleeding through chest
tubes was 350 mL per day. Seven hours postoperatively, the ACT
had returned to the control level. The postoperative course was
uneventful. Chest tubes were removed on postoperative day 3,
liver and renal function did not worsen, and the patient was dis-
charged on the 60th postoperative day. 
Discussion
Heparin is widely used as an anticoagulant for cardiac operations.
However, heparin is difficult to use in patients who have heparin-
induced thrombocytopenia, who are allergic to protamine surfate,
or who have low levels of AT III. Especially in patients with
heparin-induced thrombocytopenia, reexposure to heparin is asso-
ciated with a high risk for the development of arterial and venous
thrombosis. An ideal substitute for heparin during cardiac opera-
tions is being sought for those patients. 
Danaparoid sodium and hirudin are the main substitutes for
heparin currently available for anticoagulation during heart
surgery. However, potential disadvantages of their use include dif-
ficulty in monitoring anticoagulant levels and irreversible effects.
Argatroban ([2R, 4R]-4-methyl-1-[N-(3-methyl-1,2,3,4 tetrahy-
dro-8-quinolinesulfonyl)-L-arginyl]-2-piperidine carboxylic acid)
is a low-molecular-weight arginine derivative that binds thrombin
competitively.1 Compared with heparin, hirudin, and danaparoid
sodium, argatroban has several potential advantages.2 It does not
need AT III as a cofactor, and it is non-antigenic. The anticoagu-
lant effect is concentration-dependent, compromises both free and
clot-bound thrombin, and exhibits no interaction with platelets or
heparin antibodies.2 In addition, ACT can be used to monitor the
anticoagulant effect.3 The only clinical disadvantage that we
observed is that no neutralizing agent exists, such as protamine for
heparin. However, the fact that the plasma half-life of argatroban
is as short as 15 to 30 minutes compensates for the lack of a neu-
tralizing agent.3 We have been investigating argatroban as a poten-
tial anticoagulant in CPB experimentally2 and we have been using
it in various clinical situations.3 From these results, we judged that
argatroban is a potential anticoagulant in cardiac operations. In
this case, we used argatroban because of the patient’s AT III defi-
ciency and severe liver dysfunction. We based our decision on our
prior experiences and on the report by Matsuo’s group,4 which
states that argatroban deserves consideration as an anticoagulant
drug whenever patients with AT III deficiency are likely to require
an anticoagulant in the extracorporeal circuit. There have been no
adverse effects due to argatroban. However, an ACT of more than
400 seconds may be optimal for cardiac operations because of
small thrombi in the hard cardiotomy reservior.
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Figure 1. Dose of argatroban compared with activated clotting
time. ACT, Ativated clotting time; CPB, cardiopulmonary bypass. 
